Prima BioMed Long Term Debt 2010-2021 | IMMP
Prima BioMed long term debt from 2010 to 2021. Long term debt can be defined as the sum of all long term debt fields.
Prima BioMed Annual Long Term Debt
(Millions of US $) |
| 2021 |
$2 |
| 2020 |
$6 |
| 2019 |
$5 |
| 2018 |
$5 |
| 2017 |
$4 |
| 2016 |
$4 |
| 2015 |
$ |
| 2014 |
$ |
| 2013 |
$ |
| 2012 |
$ |
| 2011 |
$ |
| 2010 |
$ |
| 2009 |
$ |
Prima BioMed Quarterly Long Term Debt
(Millions of US $) |
| 2017-03-31 |
$4 |
| 2016-12-31 |
$4 |
| 2016-06-30 |
$4 |
| 2015-12-31 |
|
| 2015-06-30 |
|
| 2014-12-31 |
|
| 2014-06-30 |
|
| 2013-12-31 |
|
| 2013-06-30 |
|
| 2012-12-31 |
|
| 2012-06-30 |
|
| 2011-06-30 |
|
| 2010-06-30 |
|
| 2009-06-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.185B |
$0.003B |
|
Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the U.S. Immutep Limited, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia.
|
